Clinical trial

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types…

NCT00217230 · MedImmune LLC, Industry · Completed

Key facts

NCT number NCT00217230
Title Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older
Official title A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older CAIV-T, Liquid Formulation
Lead sponsor MedImmune LLC, Industry
Collaborators Wyeth is now a wholly owned subsidiary of Pfizer Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Influenza
Intervention type Biological
Interventions CAIV-T
Enrollment 3,000
Start date Apr 1, 2001
Completion Nov 1, 2001
First posted Sep 22, 2005
Last update posted Oct 3, 2006
Countries South Africa

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies